Table 1.
Patients’ characteristic of the matched cohorts.
| Variable | Total (n = 164) | HMA + VEN (n = 61) | 7 + 3 (n = 103) | P-value |
|---|---|---|---|---|
| Median age, years (range) | 46 (18–64) | 47(18–64) | 46 (18–64) | 0.107 |
| Male sex, n (%) | 99 (60) | 40 (66) | 59 (57) | 0.294 |
| Hematological parameters | ||||
| Median WBC, ×109/L (range) | 5.1 (0.5–258.6) | 5.11 (0.5–258.6) | 6.07 (0.77–135.7) | 0.184 |
| Median Hb, g/L (range) | 73 (36–146) | 73 (38–126) | 78 (36–146) | 0.086 |
| Median Plt, ×109/L (range) | 43 (5–303) | 43 (6–218) | 43 (5–303) | 0.780 |
| Median BM blasts, % (range) | 54.5 (20–98.5) | 54.5 (20–98.5) | 55.5 (20–98.5) | 0.932 |
| Disease type, n (%) | ||||
| De novo AML | 157 (96) | 58 (95) | 99 (96) | 1.000 |
| s-AML / t-AML | 7 (4) | 3 (5) | 4 (4) | |
| Cytogenetic abnormalities, n (%) | ||||
| MR-C | 34 (21) | 8 (13) | 26 (25) | 0.064 |
| MR-G | 94 (57) | 39 (64) | 58 (56) | 0.337 |
| MR-G/C | 36 (22) | 17 (28) | 19 (18) | 0.159 |
| Allo-HSCT, n (%) | 95 (58) | 34 (56) | 61 (59) | 0.662 |
| Co-mutations, n (%) | ||||
| Splicing factor | 51 (31) | 24 (39) | 27 (44) | 0.079 |
| U2AF1 | 30 (18) | 17 (28) | 13 (13) | 0.015 |
| SF3B1 | 10 (6) | 2 (3) | 8 (8) | 0.410 |
| SRSF2 | 11 (7) | 4 (7) | 7 (7) | 1.000 |
| ZRSR2 | 3 (2) | 3 (5) | 0 | 0.051 |
| Chromatin-cohesin | 82 (50) | 39 (64) | 43 (42) | 0.006 |
| ASXL1 | 32 (20) | 14 (23) | 18 (17) | 0.392 |
| BCOR | 36 (22) | 19 (31) | 17 (17) | 0.029 |
| EZH2 | 10 (6) | 5 (8) | 5 (5) | 0.598 |
| STAG2 | 17 (10) | 7 (11) | 10 (10) | 0.720 |
| Transcription factor | 59 (36) | 28 (46) | 31 (30) | 0.042 |
| RUNX1 | 59 (36) | 28 (46) | 31 (30) | 0.042 |
WBC White blood cell, Hb Hemoglobin, Plt Platelet, BM bone marrow, s-AML secondary AML, t-AML therapy-related AML, MR-C myelodysplasia-related cytogenetic abnormalities, MR-G myelodysplasia-related gene mutation, MR-G/C both myelodysplasia-related gene mutations and cytogenetic abnormalities, Allo-HSCT allogenetic hematopoietic stem cell transplantation.